Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.

Boyko, O; Simonova, M; Knysh, N; Danysh, O; Vygovska, Y; Masliak, Z

Boyko, O; Simonova, M; Knysh, N; Danysh, O; Vygovska, Y; Masliak, Z.

Affiliation

Boyko O; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.
Simonova M; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.
Knysh N; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.
Danysh O; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.
Vygovska Y; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.
Masliak Z; SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine", Lviv 79044, Ukraine.

Exp Oncol ; 43(1): 41-45, 2021 03.

Article de En | MEDLINE | ID: mdl-33785713

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Syndromes myélodysplasiques / Marqueurs biologiques / Érythropoïétine Type d'étude: Prognostic_studies Limites: Aged / Female / Humans / Male / Middle aged Langue: En Journal: Exp Oncol Sujet du journal: NEOPLASIAS Année: 2021 Type de document: Article Pays d'affiliation: Ukraine Pays de publication: Ukraine

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links